Codexis Enters Agreement to Manufacture 50 Grams of siRNA
Codexis announced it has entered into an agreement with "an innovator pharmaceutical company" to manufacture 50 grams of small interfering RNA using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication. Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. "We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity," said Alison Moore, President and Chief Executive Officer of Codexis. "Engagements like this illustrate our path to growth as we continue to expand partnerships and position the platform for potential commercial-scale applications."
Trade with 70% Backtested Accuracy
Analyst Views on CDXS

No data
About CDXS
About the author

- Earnings Announcement Schedule: Codexis is set to release its Q4 earnings on March 11 after market close, with market participants keenly awaiting the results, which are expected to influence stock performance.
- EPS Expectations: Analysts forecast an EPS of -$0.04, representing a 69.2% year-over-year improvement, indicating significant potential for enhanced profitability for the company.
- Revenue Growth Forecast: The revenue estimate stands at $35.83 million, reflecting a 67.0% year-over-year increase, showcasing strong market demand and sales growth that could bolster investor confidence.
- Historical Performance Insight: Historical financial data indicates that Codexis has shown gradual improvement over recent quarters, and if this earnings report meets expectations, it will further solidify its market position in the biotechnology sector.
- Strong Performance: Codexis reported a Q4 GAAP EPS of $0.11, beating expectations by $0.14, indicating a significant improvement in profitability and enhancing its competitive position in the market.
- Revenue Surge: The company achieved Q4 revenue of $38.9 million, representing an 81.3% year-over-year increase and exceeding market expectations by $3.07 million, highlighting Codexis's robust business expansion and demand.
- Positive Outlook: Total revenues are projected to range between $72 million and $76 million for 2026, providing investor confidence and indicating the company's potential for sustained growth in the coming years.
- Sufficient Funding: Codexis expects that its existing cash, cash equivalents, and short-term investments will be adequate to fund planned operations through the end of 2027, demonstrating sound financial management and sustainability.
- Partnership Agreement: Codexis has entered into an agreement with a pharmaceutical company to produce 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, which will support the preclinical development of a therapeutic candidate for cardiovascular conditions, showcasing the company's technological edge in RNA drug production.
- Surge in Revenue Expectations: Codexis is expected to release its Q4 earnings next week, with Wall Street forecasting a 67% revenue increase to $35.8 million, reflecting strong market demand for its products and potentially improving the company's financial outlook.
- Collaboration with Axolabs: The partnership with Axolabs aims to evaluate the ECO Synthesis platform, which could pave the way for future licensing opportunities and broader adoption of RNA manufacturing technology, enhancing competitive positioning in the market.
- Shift in Market Sentiment: Following the latest announcement, Stocktwits users shifted their sentiment on CDXS from neutral to bullish, indicating increased confidence in Codexis's growth potential, despite the stock having declined over 36% this year.
- Agreement Signed: Codexis has entered into an agreement with an innovative pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, supporting preclinical development for a cardiovascular therapeutic candidate, marking a significant application of its technology for large-scale production.
- Technology Advantage: The ECO Synthesis platform is designed for efficient, scalable, and high-fidelity production of complex siRNA therapeutics, addressing the increasing manufacturing demands as RNA therapeutics transition from rare diseases to larger indications, showcasing Codexis's capability to meet evolving requirements.
- Market Opportunity Expansion: CEO Alison Moore highlighted that this partnership represents an important entry point into a high-volume market opportunity, illustrating the company's growth path as it continues to expand partnerships and position the platform for potential commercial-scale applications.
- Production Capacity Enhancement: With ECO Synthesis, Codexis can achieve efficient scale-up while maintaining product consistency, which is expected to drive growth in its market share within the RNAi therapeutics sector, meeting the rising manufacturing demands.

- Agreement Overview: Codexis has signed an agreement to manufacture 50 grams of its EcoSYNTHESIS® platform.
- Purpose of Manufacturing: The manufacturing will support the development and production of innovative solutions in biotechnology.
- Partnership Agreement: Codexis and Axolabs have signed an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, aimed at enhancing the efficient manufacturing of RNA therapeutics, which is expected to significantly improve market access capabilities.
- Technological Innovation: The platform utilizes enzymatic synthesis technology, enabling more sustainable and cost-effective production to meet large-scale manufacturing demands, thereby enhancing both companies' competitiveness in the nucleic acid therapeutics sector.
- Market Potential: Codexis CEO Alison Moore stated that this collaboration will expand the reach of the ECO Synthesis Manufacturing Platform, helping to meet the rapidly growing demand for nucleic acid drugs and potentially paving the way for future licensing discussions.
- Industry Leadership: The combination of Axolabs' technological leadership and Codexis' innovative capabilities reinforces both companies' commitment to providing high-quality oligonucleotide medicines globally, driving the industry towards more efficient manufacturing models.








